Literature DB >> 34039490

The global burden of cirrhosis: A review of disability-adjusted life-years lost and unmet needs.

Peter Jepsen1, Zobair M Younossi2.   

Abstract

Cirrhosis is a burden on the individual and on public health. The World Health Organization's metric of public health burden is the disability-adjusted life-year (DALY), the sum of years of life lost due to premature death and years of life lived with disability. The more DALYs attributable to a disease, the greater its burden on public health. Cirrhosis was responsible for 26.8% fewer DALYs in 2019 than in 1990, which is positive, but the reduction in DALYs across the spectrum of diseases in and outside the liver was 34.4%. Hepatitis C (26% of DALYs), alcohol (24%), and hepatitis B (23%) contribute almost equally to the global burden of cirrhosis. The contribution from non-alcoholic fatty liver disease (8%) is small but increasing. There is substantial global variation in the burden and causes of cirrhosis. We find that the poorest countries carry the greatest burden of cirrhosis, and that this burden is primarily caused by cirrhosis from hepatitis B infection. Interventions targeting hepatitis B infection are known, but not fully implemented. In more affluent countries, alcohol and hepatitis C are the dominant causes of cirrhosis, but non-alcoholic fatty liver will likely become a dominant cause of cirrhosis in parallel with the increasing prevalence of obesity. We also argue that the World Health Organization underestimates the public health burden associated with cirrhosis because it assigns zero disability to compensated cirrhosis and considers decompensated cirrhosis as only mildly disabling.
Copyright © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cirrhosis; DALY; Epidemiology; Liver; Public health; QALY

Mesh:

Year:  2021        PMID: 34039490     DOI: 10.1016/j.jhep.2020.11.042

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  11 in total

1.  Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review.

Authors:  Catharina J Alberts; Gary M Clifford; Damien Georges; Francesco Negro; Olufunmilayo A Lesi; Yvan J-F Hutin; Catherine de Martel
Journal:  Lancet Gastroenterol Hepatol       Date:  2022-05-14

Review 2.  Liver Transplantation as a Cornerstone Treatment for Acute-On-Chronic Liver Failure.

Authors:  Martin S Schulz; Wenyi Gu; Andreas A Schnitzbauer; Jonel Trebicka
Journal:  Transpl Int       Date:  2022-03-17       Impact factor: 3.842

Review 3.  Clostridioides difficile Infection in Liver Cirrhosis: A Concise Review.

Authors:  Yuanbin Liu; Mingkai Chen
Journal:  Can J Gastroenterol Hepatol       Date:  2022-06-07

4.  New concepts and perspectives in decompensated cirrhosis.

Authors:  Rajiv Jalan; Gyongyi Szabo
Journal:  J Hepatol       Date:  2021-07       Impact factor: 30.083

5.  IL-6 and IL-10 gene polymorphisms and cirrhosis of liver risk from a comprehensive analysis.

Authors:  Minghui Zheng; Weizhen Fang; Menglei Yu; Rui Ding; Hua Zeng; Yan Huang; Yuanyang Mi; Chaohui Duan
Journal:  BMC Endocr Disord       Date:  2021-12-09       Impact factor: 2.763

Review 6.  Chronic Liver Disease in Ethiopia with a Particular Focus on the Etiological Spectrums: A Systematic Review and Meta-Analysis of Observational Studies.

Authors:  Behailu Terefe Tesfaye; Temesgen Mulugeta Feyissa; Azmeraw Bekele Workneh; Esayas Kebede Gudina; Mengist Awoke Yizengaw
Journal:  Can J Gastroenterol Hepatol       Date:  2021-11-23

7.  Acute decompensation events differentially impact the risk of nosocomial infections and short-term outcomes in patients with cirrhosis.

Authors:  Xianbin Xu; Xia Yu; Kai Gong; Huilan Tu; Junjie Yao; Yan Lan; Shaoheng Ye; Haoda Weng; Yu Shi; Jifang Sheng
Journal:  Front Med (Lausanne)       Date:  2022-08-17

8.  Role of precipitants in transition of acute decompensation to acute-on-chronic liver failure in patients with HBV-related cirrhosis.

Authors:  Tongyu Wang; Wenting Tan; Xianbo Wang; Xin Zheng; Yan Huang; Beiling Li; Zhongji Meng; Yanhang Gao; Zhiping Qian; Feng Liu; Xiaobo Lu; Huadong Yan; Yubao Zheng; Weituo Zhang; Shan Yin; Wenyi Gu; Yan Zhang; Fuchen Dong; Jianyi Wei; Guohong Deng; Xiaomei Xiang; Yi Zhou; Yixin Hou; Qun Zhang; Shue Xiong; Jing Liu; Liyuan Long; Ruochan Chen; Jinjun Chen; Xiuhua Jiang; Sen Luo; Yuanyuan Chen; Chang Jiang; Jinming Zhao; Liujuan Ji; Xue Mei; Jing Li; Tao Li; Rongjiong Zheng; Xinyi Zhou; Haotang Ren; Yu Shi; Hai Li
Journal:  JHEP Rep       Date:  2022-07-05

9.  Hepatoprotective Effect of Oyster Peptide on Alcohol-Induced Liver Disease in Mice.

Authors:  Xueqin Wang; Huahua Yu; Ronge Xing; Pengcheng Li
Journal:  Int J Mol Sci       Date:  2022-07-22       Impact factor: 6.208

10.  Identification of potential metabolic biomarkers in predicting esophageal varices needing treatment in patients with liver cirrhosis.

Authors:  Chung-Man Moon; Yun-Young Lee; Suk-Hee Heo; Sang-Soo Shin; Yong-Yeon Jeong
Journal:  Sci Rep       Date:  2021-10-04       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.